GovChime
Notice ID: c7ae3d75124841c9a085d088254088c7Award NoticeAwardedArchived

Amarillo Pharmacy Compounding-Oncology

Awarded on January 22, 2026. Full description on SAM.gov.

Awarded tounder 36C25726D0022 (source: SAM.gov award notice)• $225.0K

Overview

Posted
January 22, 2026
Notice type
Award Notice
Set-aside
No Set aside used
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of Veterans Affairs

Notice details

Office
257-NETWORK CONTRACT OFFICE 17 (36C257)
Place of performance
79106
Last updated
Nov 4, 2026
First published
Last updated on SAM.gov
Award date
Jan 22, 2026
Award amount (SAM.gov award notice)
$225.0K

Identifiers

Solicitation number
36C25726D0022-36C25726N0093
Notice ID
c7ae3d75124841c9a085d088254088c7
Award number (PIID)
36C25726D0022

Description

This was a competitive award not set aside because market research did not support a set aside.  No small businesses responded.  This is actually a modification (#P00001) for increase from the original award of $100,000 to $225,000.00 by $125,000.  This is a contingency contract for pharmacy comounding for oncology medication for Veterans. 

Full description on SAM.gov

Award Overview

Award Number

36C25726D0022

Award Amount (SAM.gov award notice)

$225.0K

Award Date

Jan 22, 2026

Awardee

Awardee UEI

RN5UVE9XMJN4

Awardee CAGE Code

9HGM2

Awardee Address

Chandler, AZ 85226, UNITED STATES

Delivery Order Number

36C25726N0093

Line Item Number

0001

Original Solicitation

Notice ID: c7ae3d75124841c9a085d088254088c7

Posted Date: Jan 22, 2026

Original Response Deadline: Not specified

Task Orders Under This IDV

Top 10 by total obligated

4
  • 36C25726N0093
    OPTUM INFUSION SERVICES 308, LLC
    Department of Veterans AffairsNAICS 325412
    $225.0KSigned Oct 27, 2025
  • 36C25726N0093
    OPTUM INFUSION SERVICES 308, LLC
    Department of Veterans AffairsNAICS 325412
    $225.0KSigned Mar 10, 2026
  • 36C25726N0093
    OPTUM INFUSION SERVICES 308, LLC
    Department of Veterans AffairsNAICS 325412
    $225.0KSigned Jan 22, 2026
  • 36C25727N0092
    OPTUM INFUSION SERVICES 308, LLC
    Department of Veterans AffairsNAICS 325412
    $100.0KSigned Oct 20, 2026

More From This Vendor

Top 5 most recent

5
  • 36C24227N0188
    OPTUM INFUSION SERVICES 308, LLC
    Department of Veterans AffairsNAICS 325412
    $20.0KSigned Oct 23, 2026
  • 36C25727N0092
    OPTUM INFUSION SERVICES 308, LLC
    Department of Veterans AffairsNAICS 325412
    $100.0KSigned Oct 20, 2026
  • 36C25727N0060
    OPTUM INFUSION SERVICES 308, LLC
    Department of Veterans AffairsNAICS 325412
    $1.2MSigned Oct 7, 2026
  • 36C26127P0001
    OPTUM INFUSION SERVICES 308, LLC
    Department of Veterans AffairsNAICS 325412
    $350.0KSigned Oct 1, 2026
  • 36C25627P0009
    OPTUM INFUSION SERVICES 308, LLC
    Department of Veterans AffairsNAICS 325412
    $396.0KSigned Oct 1, 2026

Contacts

Contracting Officer

Primary Contact

Documents

Files (1)

  • VA Amarillo - modification 36C25726D0022 36C25726N0093 P00001_FE.pdf

    287 KBAdded in Award Notice version 3Posted
    Download

Lifecycle

  1. 3
    Version 3Award NoticeArchivedCurrent

    Amarillo Pharmacy Compounding-Oncology

    Notice c7ae3d75124841c9a085d088254088c7 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Central Alabama Veterans Healthcare System Radiopharmaceuticals
54%
Special Notice09/15/2026
QUESTIONS AND ANSWERS Q: Please clarify whether prescription drug ingredient costs reimbursed to participating retail pharmacies are considered pass-through costs or included in the 50% limitations on subcontracting calculation, and whether pharmacy dispensing fees are treated differently. A: This procurement is a services contract subject to the limitations on subcontracting requirements in VAAR 852.219-75. Prescription drug ingredient costs reimbursed to participating retail pharmacies are considered pass-through/direct reimbursement costs and are not considered service performance costs for purposes of the 50% subcontracting calculation. Pharmacy dispensing fees, however, are compensation for pharmacy services performed and are included in the limitations on subcontracting analysis unless performed by a similarly situated certified SDVOSB subcontractor. Offerors remain responsible for ensuring compliance with all applicable SBA and VA limitations on subcontracting requirements.
45%
Solicitation11/23/2026
This is a PRE-SOLICITATION NOTICE ONLY. This is not a request for proposal, quotation, or bid. The Network Contracting Office 15 (NCO15), 3450 S 4th Street | Leavenworth, KS 66048 intends to issue a solicitation for a VOSB/SDVOSB set-aside, single award, Indefinite Delivery/indefinite Quantity Contract. The contract will cover the contractor provided third party pharmacy benefit services to support a First Fill Prescription Voucher Program serving eligible Veterans. This program provides first or urgent fill prescriptions when VA pharmacies are unable or impractical to dispense medications, such as after hours emergency room visits, time sensitive medications from Community Based Outpatient Clinics (CBOCs), Home Based Primary Care (HBPC), or telehealth appointments. The NAICS Code is 524292 Pharmacy Benefit Management and Other Third-Party Administration of Insurance and Pension Funds, NAICS Size Standard $4.5million. The Product Service Code is Q517 Pharmacy Services. All potential vendors MUST be registered and active in the SAM. SDVOSB/VOSB vendors must be registered in the SBA VetCert database. The solicitation will be issued electronically and will be available only via the Contract Opportunities / System for Award Management website www.sam.gov. No fax bid packages shall be accepted. The solicitation will be publicized on or about November 1st, 2026. No phone, fax or email inquiries will be taken for this Pre-Solicitation Notice
44%
Pre-Solicitation11/16/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed: Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA Emcitate – Thyroid and Antithyroid Agents – Subclass: NA Hibsago – Hepatitis B Agents – Subclass: NA Juvmo – Parkinsons Agents – Subclass: NA Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9102. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
43%
Solicitation11/30/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 drug classes/subclasses will be reviewed: a. Ophthalmic - Dry Eye Cequa Eysuvis Miebo Tryptyr Tyrvaya Verkazia Vevye Xiidra b. Testosterone Replacement Therapy - Orals Jatenzo Kyzatrex Tlando The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9101. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.
43%
Solicitation12/07/2026

Additional Details

Solicitation Number

36C25726D0022-36C25726N0093

Archive Date

Feb 6, 2026

Office Address

San Antonio, TX, 78240